MCID: TTH006
MIFTS: 54

Tooth Disease

Categories: Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Tooth Disease

MalaCards integrated aliases for Tooth Disease:

Name: Tooth Disease 12 14
Tooth Diseases 41 69
Tooth Disorders 40

Classifications:



External Ids:

Disease Ontology 12 DOID:1091
MeSH 41 D014076
ICD10 32 K02.9
UMLS 69 C0040435

Summaries for Tooth Disease

MedlinePlus : 40 Your teeth are made of a hard, bonelike material. Inside the tooth are nerves and blood vessels. You need your teeth for many activities you may take for granted. These include eating, speaking and even smiling. But tooth disorders are nothing to smile about. They include problems such as cavities (also known as tooth decay), infections, and injuries. The most familiar symptom of a tooth problem is a toothache. Others include worn-down or loose teeth. It's important that you see a dentist if you have any problems with your teeth. Fortunately, you can prevent many tooth disorders by taking care of your teeth and keeping them clean.

MalaCards based summary : Tooth Disease, also known as tooth diseases, is related to charcot-marie-tooth disease, axonal, type 2j and charcot-marie-tooth disease, x-linked dominant, 1, and has symptoms including poor dentition, toothache and snoring. An important gene associated with Tooth Disease is GJB1 (Gap Junction Protein Beta 1), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Acetylcholine and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and heart, and related phenotypes are behavior/neurological and mortality/aging

Related Diseases for Tooth Disease

Diseases related to Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2j 34.3 KIF1B MPZ
2 charcot-marie-tooth disease, x-linked dominant, 1 34.3 GDAP1 GJB1 MPZ
3 charcot-marie-tooth disease, type 4b1 34.2 GDAP1 MTMR2 SBF1
4 charcot-marie-tooth disease, type 4b2 34.2 GDAP1 MTMR2 SBF1
5 charcot-marie-tooth disease, axonal, type 2k 34.2 GDAP1 KIF1B MFN2
6 charcot-marie-tooth disease, type 4j 34.2 FIG4 GDAP1 MTMR2
7 charcot-marie-tooth disease, axonal, type 2a1 34.2 KIF1B MFN2
8 charcot-marie-tooth disease, type 4d 34.2 GDAP1 GJB1 MFN2 SH3TC2
9 charcot-marie-tooth disease, axonal, type 2l 34.2 HSPB1 KIF1B MPZ
10 charcot-marie-tooth disease, type 4b3 34.2 GDAP1 MTMR2 SBF1
11 charcot-marie-tooth disease, demyelinating, type 4f 34.1 GDAP1 MTMR2
12 charcot-marie-tooth disease, axonal, type 2i 34.1 KIF1B MPZ
13 charcot-marie-tooth disease, type 4c 34.1 GDAP1 SH3TC2
14 charcot-marie-tooth disease type 2a 34.1 KIF1B MFN2
15 charcot-marie-tooth disease, demyelinating, type 1f 34.1 GJB1 MPZ NEFL PMP22
16 charcot-marie-tooth disease, axonal, type 2f 34.1 GJB1 HSPB1 KIF1B MPZ
17 charcot-marie-tooth disease, axonal, type 2b 34.0 EGR2 GJB1 KIF1B MPZ PMP22
18 charcot-marie-tooth disease, type 4a 33.9 GDAP1 MTMR2
19 charcot-marie-tooth disease type 2g 33.9 GDAP1 LRSAM1
20 x-linked charcot-marie-tooth disease 33.9 GJB1 PRPS1
21 charcot-marie-tooth disease, x-linked recessive, 5 33.9 GJB1 PRPS1
22 charcot-marie-tooth disease, demyelinating, type 1b 33.9 EGR2 GJB1 KIF1B MPZ MTMR2 PMP22
23 charcot-marie-tooth disease, demyelinating, type 1d 33.8 EGR2 GJB1 KIF1B MPZ MTMR2 PMP22
24 charcot-marie-tooth disease, demyelinating, type 1c 33.6 EGR2 GJB1 KIF1B LITAF MPZ MTMR2
25 charcot-marie-tooth disease, demyelinating, type 1a 33.6 EGR2 GDAP1 GJB1 KIF1B MFN2 MPZ
26 neuropathy, hereditary motor and sensory, russe type 33.3 EGR2 SH3TC2
27 charcot-marie-tooth disease and deafness 33.2 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
28 hereditary motor and sensory neuropathy, type iic 33.1 GDAP1 GJB1 KIF1B MFN2 MPZ
29 charcot-marie-tooth disease, axonal, type 2e 32.8 EGR2 GARS GDAP1 GJB1 KIF1B LMNA
30 foot drop 32.4 MPZ PMP22
31 hypertrophic neuropathy of dejerine-sottas 32.3 EGR2 GDAP1 GJB1 KIF1B LITAF MPZ
32 roussy-levy hereditary areflexic dystasia 32.1 GDAP1 HSPB1 KIF1B LMNA LRSAM1 MFN2
33 hereditary neuropathies 31.8 GJB1 LMNA MFN2 MPZ MTMR2 PMP22
34 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 31.8 EGR2 FGD4 FIG4 GDAP1 GJB1 KIF1B
35 congenital hypomyelination neuropathy 31.2 EGR2 FGD4 FIG4 MPZ MTMR2 PMP22
36 neuropathy 31.1 EGR2 GDAP1 GJB1 MFN2 MPZ PMP22
37 hereditary neuropathy with liability to pressure palsy 31.0 LITAF MPZ PMP22
38 charcot-marie-tooth disease 30.9 EGR2 FGD4 FIG4 GARS GDAP1 GJB1
39 polyneuropathy 30.8 GDAP1 MPZ PMP22
40 neuropathy, hereditary, with liability to pressure palsies 30.1 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
41 cauda equina syndrome 30.1 EGR2 PMP22
42 early-onset glaucoma 30.0 MTMR2 SBF1
43 axonal neuropathy 29.9 GARS GDAP1 LMNA MFN2 PMP22
44 charcot-marie-tooth disease, axonal, type 2b2 12.4
45 charcot-marie-tooth disease, type 4h 12.4
46 charcot-marie-tooth disease, axonal, type 2d 12.4
47 charcot-marie-tooth disease, axonal, type 2p 12.4
48 charcot-marie-tooth disease, axonal, type 2t 12.3
49 charcot-marie-tooth disease, axonal, type 2n 12.3
50 charcot-marie-tooth disease, axonal, type 2b1 12.3

Graphical network of the top 20 diseases related to Tooth Disease:



Diseases related to Tooth Disease

Symptoms & Phenotypes for Tooth Disease

UMLS symptoms related to Tooth Disease:


poor dentition, toothache, snoring, halitosis

MGI Mouse Phenotypes related to Tooth Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 MFN2 GJB1 MPZ KIF1B EGR2 FGD4
2 mortality/aging MP:0010768 10.1 MFN2 GJB1 KIF1B EGR2 LMNA FIG4
3 cellular MP:0005384 10.07 GDAP1 MFN2 GJB1 HSPB1 EGR2 LITAF
4 limbs/digits/tail MP:0005371 9.92 GDAP1 KIF1B EGR2 LMNA FIG4 MED25
5 nervous system MP:0003631 9.86 MFN2 GJB1 MPZ KIF1B EGR2 LITAF
6 muscle MP:0005369 9.7 MFN2 KIF1B LMNA FIG4 GARS SH3TC2
7 normal MP:0002873 9.23 MFN2 HSPB1 EGR2 LMNA LRSAM1 GARS

Drugs & Therapeutics for Tooth Disease

Drugs for Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 405)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
2
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 55-56-1 2713 9552079
3
Tea tree oil Approved Phase 4
4
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
5
Ephedrine Approved Phase 4 299-42-3 9294
6
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
7
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
8
Phenylephrine Approved Phase 4 59-42-7 6041
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
Hydrogen peroxide Approved, Vet_approved Phase 4,Phase 3,Phase 1 7722-84-1 784
13 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7681-49-4
14
Diclofenac Approved, Vet_approved Phase 4,Phase 2,Phase 3 15307-86-5 3033
15
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 26787-78-0 33613 2171
16
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
17
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 69-72-7 338
18
Ibuprofen Approved Phase 4,Phase 3,Phase 2 15687-27-1 3672
19
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
20
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Early Phase 1 22916-47-8 4189
22
Sorbitol Approved Phase 4,Phase 2,Phase 3 50-70-4 5780
23
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2 64-17-5 702
24
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
25
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Early Phase 1 50-02-2 5743
26
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
27
Codeine Approved, Illicit Phase 4,Phase 3,Phase 2 76-57-3 5284371
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 93-14-1 3516
29
Esomeprazole Approved, Investigational Phase 4,Phase 1,Phase 2 161796-78-7, 119141-88-7 9579578 4594
30
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22204-53-1 156391 1302
31
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
32 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 329-65-7
33
Piroxicam Approved, Investigational Phase 4,Phase 3 36322-90-4 54676228 5280452
34
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
36
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
37
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 27203-92-5 33741
38
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
39
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3 59467-70-8 4192
40
Alginic acid Approved, Experimental, Investigational Phase 4 9005-32-7
41
Silicon Approved, Investigational Phase 4,Phase 3 7440-21-3 4082203
42 Cetylpyridinium Approved Phase 4,Phase 3,Phase 2,Phase 1 7773-52-6
43
Triclosan Approved, Investigational Phase 4,Phase 3,Phase 2 3380-34-5 5564
44
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
45
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Early Phase 1 103-90-2 1983
46
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 38396-39-3, 2180-92-9 2474
47
Hydrocodone Approved, Illicit Phase 4,Phase 2 125-29-1 5284569
48
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
49
Capsaicin Approved Phase 4 404-86-4 1548943
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 1276)

# Name Status NCT ID Phase Drugs
1 Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars Unknown status NCT02286648 Phase 4 Formocresol;Mineral Trioxide Aggregate
2 Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT Unknown status NCT02702505 Phase 4
3 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
4 Effect of Different Mouthrinses in Plaque Formation Unknown status NCT02695901 Phase 4 Chlorhexidine gluconate 0.12% (PerioGard®);Nanoparticle solution of M. alternifolia oil (0.3%).
5 Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children. Unknown status NCT02692625 Phase 4
6 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
7 Manually Versus Digitally Fabricated Removable Partial Dentures Unknown status NCT01191073 Phase 4
8 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
9 Clinical Comparison of RPDs Retained by Conical and Galvanoformed Double Crowns. Unknown status NCT00176215 Phase 4
10 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
11 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
12 Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). Unknown status NCT01778699 Phase 4
13 Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel Unknown status NCT00846690 Phase 4 benzocaine;TAC alternate gel
14 Ketamine on Acute Pain in Females and Males Completed NCT00232492 Phase 4 Placebo males;Ketamine 0,1 mg/kg males;Ketamine 0,3 mg/kg males;Ketamine 0,5 mg/kg males;Placebo females;Ketamine 0,1 mg/kg females;Ketamine 0,3 mg/kg females;Ketamine 0,5 mg/kg females
15 The Effect of Whitening Toothpaste on Tooth Color Associated With Bleaching Process Completed NCT03163069 Phase 4
16 Efficacy of a Whitening Dentifrice on Tooth Discoloration Completed NCT02741427 Phase 4
17 Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction. Completed NCT02547896 Phase 4 Codeine + Diclofenac;Diclofenac
18 Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal Completed NCT02494856 Phase 4 Surgery with Naproxen;Surgery with Naproxen and Esomeprazole
19 Lower Third Molar Removal With 2% and 4% Articaine Completed NCT02457325 Phase 4 Surgery with 2% articaine;Surgery with 4% articaine
20 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery Completed NCT02450487 Phase 4 Piroxicam
21 AUGMENTIN™ in Dental Infections Completed NCT02141217 Phase 4 Amoxicillin/clavulanate;Clindamycin
22 Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients Completed NCT02017873 Phase 4 Peroxide Carbamide 10% - Dental bleaching treatment
23 An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining Completed NCT01962493 Phase 4 Chlorhexidine digluconate
24 Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners Completed NCT01962012 Phase 4
25 Clinical Effectiveness of In-office Bleaching Activated With a LED/Laser Device Completed NCT01231243 Phase 4
26 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
27 Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks Completed NCT03426150 Phase 4 CPP-ACP;Placebos
28 Treatment of Immature Permanent Teeth With Three Different Pulp Capping Materials With Partial Pulpotomy Completed NCT03426046 Phase 4 Pulp Capping Agents
29 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Completed NCT02953886 Phase 4
30 To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH) Completed NCT02923895 Phase 4
31 Nano-hydroxyapatite With Potassium Nitrate in the Therapy of the Dental Sensitivity Completed NCT02895321 Phase 4
32 Oral Glucocorticoids Effect on Post Endodontic Pain Completed NCT02819648 Phase 4 Prednisolone
33 Fuji Type VII Sealant Versus Resin Based Sealant. A Clinical Trial Completed NCT02795728 Phase 4
34 Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity Completed NCT02773758 Phase 4
35 Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02731833 Phase 4
36 Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars Completed NCT02592278 Phase 4 Fluoride Varnish;Control Group
37 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
38 Clinical Study of the Whitening Dentifrices on Tooth Color and Sensitivity Completed NCT02483013 Phase 4
39 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
40 Preventive and Therapeutic Proximal Sealants Completed NCT02338180 Phase 4
41 The Effect of Desensitizing Agents in In-home or In-office Dental Bleaching Completed NCT02316080 Phase 4
42 Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis Completed NCT02110966 Phase 4 Mepivacaine;Mepivacaine plus Tramadol
43 Dexketoprofen Trometamol in Postoperative Endodontic Pain Completed NCT02086097 Phase 4 Dexketoprofen trometamol;Ibuprofen;PLACEBO
44 Anesthetic Efficacy in Irreversible Pulpitis Completed NCT02054767 Phase 4 Intervention: inferior alveolar nerve block injection
45 Impact of Maternal Xylitol Consumption on Mutans Sterptococci Completed NCT02036151 Phase 4 xylitol;fluoride varnish application
46 Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits Completed NCT01912755 Phase 4 4% articaine with 1:100,000 epinephrine;2% lidocaine with 1:100,000 epinephrine
47 Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients Completed NCT01768390 Phase 4
48 Fluoride Varnish For Childsmile Nursery School Attenders Completed NCT01674933 Phase 4 Duraphat® Fluoride Varnish
49 Postoperative Pulpal Complications in Posterior Resin Composite Restorations Without Glass-ionomer Cement Lining Completed NCT01567514 Phase 4
50 Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride Completed NCT01563172 Phase 4 Sodium fluoride / silica and carbopol, 0.5g;Sodium fluoride / silica and carbopol, 1.5g;Sodium fluoride / silica and carbopol, 1.5g

Search NIH Clinical Center for Tooth Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: tooth diseases

Genetic Tests for Tooth Disease

Anatomical Context for Tooth Disease

MalaCards organs/tissues related to Tooth Disease:

38
Bone, Testes, Heart, Brain, Spinal Cord, Tonsil, Colon

Publications for Tooth Disease

Articles related to Tooth Disease:

(show top 50) (show all 1025)
# Title Authors Year
1
Peripheral neuropathies: Antisense therapy for Charcot-Marie-Tooth disease? ( 29269786 )
2018
2
A novel mutation of LRSAM1 in a Chinese family with Charcot-Marie-Tooth disease. ( 29341362 )
2018
3
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. ( 29243538 )
2018
4
Clinical and genetic features of Charcot-Marie-Tooth disease 2F and hereditary motor neuropathy 2B in Japan. ( 29381233 )
2018
5
Six months of strength training reduces progression of dorsiflexor muscle weakness in children with Charcot-Marie-Tooth disease [synopsis]. ( 29276065 )
2018
6
SCO2 mutations cause early-onset axonal Charcot-Marie-Tooth disease associated with cellular copper deficiency. ( 29351582 )
2018
7
Six months of strength training reduces progression of dorsiflexor muscle weakness in children with Charcot-Marie-Tooth disease [commentary]. ( 29289585 )
2018
8
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. ( 29415205 )
2018
9
Substitution impact of highly conserved arginine residue at position 75 in GJB1 gene in association with X-linked Charcot-Marie-tooth disease: A computational study. ( 29111421 )
2018
10
Small heat shock protein B3 (HSPB3) mutation in an axonal Charcot-Marie-Tooth disease family. ( 29341343 )
2018
11
Neurofilament light, biomarkers, and Charcot-Marie-Tooth disease. ( 29321227 )
2018
12
Charcot-Marie-Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease. ( 29215088 )
2018
13
Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease. ( 29246265 )
2018
14
PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. ( 29449460 )
2018
15
Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs. ( 29276154 )
2018
16
Operative treatment algorithm for foot deformities in Charcot-Marie-Tooth disease. ( 29417158 )
2018
17
A novel mutation in FGD4 causes Charcot-Marie-Tooth disease type 4H with cranial nerve involvement. ( 28847448 )
2017
18
Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2. ( 28581500 )
2017
19
A Novel Missense Mutation in Peripheral Myelin Protein-22 Causes Charcot-Marie-Tooth Disease. ( 28748849 )
2017
20
Rapid Identification of Pathogenic Variants in Two Cases of Charcot-Marie-Tooth Disease by Gene-Panel Sequencing. ( 28379183 )
2017
21
Clinical and mutational spectrum of Japanese patients with Charcot-Marie-Tooth disease caused by GDAP1 variants. ( 28244113 )
2017
22
Phenotypic spectrum of Charcot-Marie-Tooth disease due to LITAF/SIMPLE mutations: a study of 18 patients. ( 28211240 )
2017
23
A longitudinal clinicopathological study of two unrelated patients with Charcot-Marie-Tooth disease type 1E. ( 28681776 )
2017
24
Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score. ( 28914656 )
2017
25
Brain involvement in Charcot-Marie-Tooth disease due to ganglioside-induced differentiation associated-protein 1 mutation. ( 28673555 )
2017
26
Molecular Epidemiology of Charcot-Marie-Tooth Disease in Northern Ostrobothnia, Finland: A Population-Based Study. ( 28810241 )
2017
27
Erratum: Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease. ( 27995668 )
2017
28
Phenotypical features of a new dominant GDAP1 pathogenic variant (p.R226del) in axonal Charcot-Marie-Tooth disease. ( 28236508 )
2017
29
Established and novel measures of upper limb impairment in children with Charcot-Marie-tooth disease type 1A and riboflavin transporter deficiency type 2. ( 29168276 )
2017
30
Gait patterns of children and adolescents with Charcot-Marie-Tooth disease. ( 28527386 )
2017
31
Whole-Exome Sequencing Identifies a Novel Homozygous Frameshift Mutation in the MTMR2 Gene as a Causative Mutation in a Patient with Charcot-Marie-Tooth Disease Type 4B1. ( 28509084 )
2017
32
Traduction franAsaise de l'Acchelle Charcot-Marie-Tooth Disease Pediatric Scale. ( 28814348 )
2017
33
Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease. ( 28438772 )
2017
34
Confirmation of the GNB4 gene as causal for Charcot-Marie-Tooth disease by a novel de novo mutation in a Czech patient. ( 27908631 )
2017
35
Unilateral oculomotor palsy in Charcot-Marie-Tooth disease 1A (CMT 1A). ( 28214652 )
2017
36
Long-Term Effective Thalamic Deep Brain Stimulation for Neuropathic Tremor in Two Patients with Charcot-Marie-Tooth Disease. ( 28297702 )
2017
37
New mutation in a patient with Charcot-Marie-Tooth disease. ( 28318735 )
2017
38
Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review. ( 28364294 )
2017
39
Motor neuron disease of very long disease duration or Charcot-Marie-Tooth disease? A novel phenotype related to the SOD1 p.E22G variant. ( 28579206 )
2017
40
Clinical characterization and genetic analysis of Korean patients with X-linked Charcot-Marie-Tooth disease type 1. ( 28448691 )
2017
41
Targeted exomes reveal simultaneous MFN2 and GDAP1 mutations in a severe Charcot-Marie-Tooth disease type 2 phenotype. ( 28211244 )
2017
42
Anatomical distributional defects in mutant genes associated with dominant intermediate Charcot-Marie-Tooth disease type C in an adenovirus-mediated mouse model. ( 28469666 )
2017
43
Frequency and circumstances of falls for people with Charcot-Marie-Tooth disease: A cross sectional survey. ( 29282812 )
2017
44
Centrally involved X-linked Charcot-Marie-Tooth disease presenting as a stroke-mimic. ( 28097225 )
2017
45
Identification and functional characterization of two missense mutations in NDRG1 associated with Charcot-Marie-Tooth disease type 4D. ( 28776325 )
2017
46
Charcot-Marie-Tooth disease type 1C: Clinical and electrophysiological findings for the c.334G>a (p.Gly112Ser) Litaf/Simple mutation. ( 28164329 )
2017
47
Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients. ( 29246495 )
2017
48
Rigid spine syndrome associated with sensory-motor axonal neuropathy resembling Charcot-Marie-Tooth disease is characteristic of Bcl-2-associated athanogene-3 gene mutations even without cardiac involvement. ( 28224639 )
2017
49
Fifteen-year longitudinal follow-up of a patient with severe early-onset Charcot-Marie-Tooth disease type 2A. ( 29266326 )
2017
50
Nine-hole Peg Test and Ten-meter Walk Test for Evaluating Functional Loss in Chinese Charcot-Marie-Tooth Disease. ( 28748848 )
2017

Variations for Tooth Disease

Expression for Tooth Disease

Search GEO for disease gene expression data for Tooth Disease.

Pathways for Tooth Disease

Pathways related to Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 GJB1 MPZ PMP22

GO Terms for Tooth Disease

Cellular components related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 FGD4 GARS GDAP1 HSPB1 LITAF LMNA
2 early endosome membrane GO:0031901 9.33 FIG4 LITAF MTMR2
3 axon cytoplasm GO:1904115 8.8 HSPB1 KIF1B NEFL

Biological processes related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anterograde axonal transport GO:0008089 9.46 KIF1B NEFL
2 peripheral nervous system development GO:0007422 9.43 EGR2 PMP22
3 phosphatidylinositol biosynthetic process GO:0006661 9.43 FIG4 MTMR2 SBF1
4 phosphatidylinositol metabolic process GO:0046488 9.4 FIG4 MTMR2
5 mitochondrial fusion GO:0008053 9.37 GDAP1 MFN2
6 negative regulation of endocytosis GO:0045806 9.32 LRSAM1 MTMR2
7 myelin assembly GO:0032288 9.16 FIG4 MTMR2
8 negative regulation of myelination GO:0031642 8.96 FIG4 MTMR2
9 myelination GO:0042552 8.8 EGR2 MPZ PMP22

Molecular functions related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-3-phosphatase activity GO:0004438 8.62 FIG4 MTMR2

Sources for Tooth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
61